News

AddToAny

Google+ Facebook Twitter Twitter

New biomarker to prevent graft-versus-host disease

A recent report sheds light on immune cell biomarkers that may reveal which patients are most at risk for graft-versus-host disease (GVHD).

This is a life-threatening condition that can arise after haematopoietic stem cell transplantation (HSCT) for treatment of blood cancers, such as leukaemia.

Sophie Paczesny, lead author, said: “Allogeneic HSCT remains the only validated treatment to cure leukaemia. 

“In HSCT, donor-matched cells are infused into the bloodstream of sick patients and ultimately travel to the bone marrow. Some of these cells are immune cells, which help eliminate residual leukaemia cells not killed by chemotherapy. 

“Yet despite careful donor-recipient matching and use of immunosuppressive therapies following transplantation, some of the donor’s immune cells may begin to attack the patient’s tissues, which is called graft-versus-host disease.”

GVHD impacts up to 50% of patients receiving HSCT and can manifest in multiple organs. About a third of those with GVHD experience localised effects within the gastrointestinal tract (GI-GVHD), which carries the highest risk for fatality.

Paczesny’s group showed that levels of dendritic cells (specifically a population known as plasmacytoid dendritic cells) expressing the ICOS ligand were increased in patients with GI-GVHD compared with controls. Critically, patients with high levels of these cells had significantly lower three-year survival outcomes compared with those with low levels. 

bit.ly/33GQEkJ

Image Credit: Shutterstock

Related Articles

genetics mutations cancer - CREDIT - alamy-2jkftm9

The evolution of cancer

Charlie Swanton outlines the work in cancer research that led to him being awarded a 2024 Louis-Jeantet Prize for translational medicine.

A nurse takes the blood pressures of a woman as she waits with an infant at Ndirande Health Centre in Blantyre on February 21, 2018 - Image credit - Getty-922184246

Vaccine effective in preventing typhoid fever

A single dose of the typhoid conjugate vaccine Typbar TCV provides lasting efficacy in preventing typhoid fever in children aged nine months to 12 years old, according to a new study.

Immune system defends the body against infections and diseases-Credit-istock-1215808904

Autoimmune diseases revisited: part 3

Is autoimmunity on the increase? Epidemiological evidence. Details of five autoimmune diseases are presented.

white cells attacking cancer - CREDIT- Science Photo Library f0234989.jpg

Taming the chaotic protein that fuels cancers

MYC is a protein that it is claimed is responsible for making the majority of human cancer cases worse.

Top